Join Growin Stock Community!

光晟生技7561.TW Overview

TW StockBiotech. & Medical
(No presentation for 7561)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

光晟生技（7561）Overall Performance

光晟生技（7561）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

光晟生技（7561） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

光晟生技（7561）Key Information

光晟生技（7561）Profile

Bioray Biotech Co., Ltd engages in the research and development, manufacture, and sale of biological and health supplement products. Its biological products include functional probiotics, medicinal fungi, and immune cell preparations. The company is also involved in the cell testing and storage business. Bioray Biotech Co., Ltd was founded in 1994 is based in Pingtung, Taiwan.

光晟生技（7561）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.63
PE Ratio (TTM)
39.15
Forward PE
-
PS Ratio (TTM)
1.76
PB Ratio
1.69
Price-to-FCF
22.71
METRIC
VALUE
vs. INDUSTRY
Gross Margin
43.91%
Net Margin
4.49%
Revenue Growth (YoY)
24.59%
Profit Growth (YoY)
25.33%
3-Year Revenue Growth
0.79%
3-Year Profit Growth
-5.48%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.63
PE Ratio (TTM)
39.15
Forward PE
-
PS Ratio (TTM)
1.76
PB Ratio
1.69
Price-to-FCF
22.71
Gross Margin
43.91%
Net Margin
4.49%
Revenue Growth (YoY)
24.59%
Profit Growth (YoY)
25.33%
3-Year Revenue Growth
0.79%
3-Year Profit Growth
-5.48%
default symbol

7561

光晟生技

24.65D

2.23%

(0.02)

  • When is 7561's latest earnings report released?

    The most recent financial report for 光晟生技 (7561) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7561's short-term business performance and financial health. For the latest updates on 7561's earnings releases, visit this page regularly.

  • Where does 7561 fall in the P/E River chart?

    According to historical valuation range analysis, 光晟生技 (7561)'s current price-to-earnings (P/E) ratio is 17.96, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much cash does 7561 have?

    At the end of the period, 光晟生技 (7561) held Total Cash and Cash Equivalents of 154.87M, accounting for 0.3 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 7561 go with three margins increasing?

    In the latest report, 光晟生技 (7561) achieved the “three margins increasing” benchmark, with a gross margin of 49.73%%, operating margin of 20.58%%, and net margin of 16.85%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 7561's profit trajectory and future growth potential.